US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- A small group of NFL rookies from the 2024 class, including Caleb Williams and Drake Maye, sat down2024-05-21
AP Week in Pictures: Europe and Africa
April 19-25, 2024French police evict migrants from a makeshift camp in Paris ahead of the Olympics,2024-05-21- LONDON (AP) — Scotland’s leader insisted Friday that he won’t be resigning as he fights for his poli2024-05-21
Fall in love with Chinese instrument hulusi flute
WELLINGTON, Sept. 26 (Xinhua) -- David Stringer is a star in the Chinese community in New Zealand's2024-05-21OpenAI pauses ChatGPT voice after Scarlett Johansson comparisons
NEW YORK (AP) — OpenAI says it plans to halt the use of one of its ChatGPT voices after some users s2024-05-21Eminem announces his 12th studio album The Death of Slim Shady (Coup de Grace) with a true
Just before Detroit legend Eminem took the stage in Motor City to kick off the NFL Draft, the rapper2024-05-21
atest comment